A Prospective, Multi-arm, Multi-center Clinical Trial on Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer
Latest Information Update: 18 Aug 2022
Price :
$35 *
At a glance
- Drugs Rezvilutamide (Primary) ; Abiraterone acetate; Apalutamide; Darolutamide; Enzalutamide; Fuzuloparib; Goserelin; Leuprorelin; Olaparib; Pamiparib; Prednisolone acetate; Talazoparib; Triptorelin
- Indications Prostate cancer
- Focus Therapeutic Use
- 13 Jul 2022 Planned primary completion date changed from 31 Dec 2029 to 31 Dec 2026.
- 13 Jul 2022 Status changed from not yet recruiting to recruiting.
- 15 Jun 2022 New trial record